1 deck published between 2019-03-21 and 2019-03-21 — 83 pages, 83 analysed slides total.
Each deck in chronological order — click to open. This is the story of the campaign as it unfolded.
Dexcom's blow-out growth is a sugar high — driven by hidden price hikes and sensor stockpiling — and Abbott's cheap Libre 2 will commoditize CGMs, taking DXCM down 45-60% to $65-$85.